AstraZeneca has launched in the UK a new pre-filled pen containing its once-weekly diabetes drug Bydureon (exenatide), offering patients a simpler route of administration. AstraZeneca has launched in ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...

US regulators have given the thumbs-up to AstraZeneca's pre-filled, single-use pen injector version of its long-acting diabetes drug Bydureon. US regulators have given the thumbs-up to AstraZeneca’s ...

If you have type 2 diabetes, your doctor may recommend Bydureon BCise as a treatment. It’s used with a balanced diet and exercise to help manage blood sugar. Bydureon BCise is used in adults and ...

AstraZeneca (AZ) has finally secured US approval for a pen injector version of its once-weekly diabetes drug Bydureon after a delay of more than a year. Bydureon Pen (exenatide) had been due to reach ...

With a view to improve treatment for diabetes patients through innovative technology, product design and development firm Cambridge Consultants in association with AstraZeneca have developed Bydureon ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that once-weekly BYDUREON ® (exenatide extended-release for injectable suspension) Pen 2 mg, a prescription medicine, is now ...

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...

AstraZeneca’s newly formulated Bydureon BCise (exenatide extended-release) has received US approval from the Food and Drug Administration (FDA) for adults with type 2 diabetes whose blood sugar ...

AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug. Bydureon (exenatide), a ...

As it approaches the end of a distinguished run, AstraZeneca’s type 2 diabetes franchise is showing its age. Sales are in decline for Byetta and Bydureon as they’ve been squeezed by formidable foes in ...